Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer

Lignende værker

• HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
  af: Rinnerthaler, Gabriel, et al.
  Udgivet: (2019)
• T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
  af: Nicoletti, Roberta, et al.
  Udgivet: (2014)
• Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
  af: Girish, Sandhya, et al.
  Udgivet: (2012)
• T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
  af: English, Diana P, et al.
  Udgivet: (2014)
• Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
  af: Lu, Dan, et al.
  Udgivet: (2014)